Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Saving lives – with and beyond dialysis

On the occasion of Fresenius Medical Care's 25th anniversary, CEO Rice Powell and Global Chief Medical Officer Franklin W. Maddux, MD, discuss ways to further improve the lives of kidney disease patients.
Read the story
Doubling up on a second chance

Twin brothers Kilian and Jamie both suffered from a heart weakness. Just three days apart, they each received a transplanted heart at Fresenius Helios.
Read the story
The moments that last forever

What is the true value of health to our lives? And what contribution are we making at Fresenius? Watch our new animated image film!
Watch the image film
A robot at the operating table

Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Read the story

News

Fresenius Medical Care’s new FX CorAL dialyzer combines clinical performance with hemocompatibility

Fresenius Medical Care is launching a new dialyzer for hemodialysis, the FX CorAL^®. Focal points of the new dialyzer’s development were clinical performance and hemocompatibility.
November 29, 2021Fresenius Medical Care
Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia.
November 22, 2021Fresenius Helios
Brief News
Fresenius SE & Co. KGaA again included in Dow Jones Sustainability Index

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent based on the international investment company S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Cybersecurity, Data Protection and Human Rights. In the area of Partnerships towards sustainable healthcare, Fresenius was awarded the maximum score in the rating 2021.

November 16, 2021Fresenius

Brief News
Fresenius Medical Care included for 12th time in Dow Jones Sustainability Index

Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has been recognized for the 12th time as a sustainability leader, with inclusion in the Dow Jones Sustainability Index. The DJSI Europe is composed of the top 20 percent of the largest 600 European companies listed in the S&P Global BMI, based on the international investment company S&P Global’s analysis of their economic, environmental and social performance. Fresenius Medical Care achieved improvements in most categories and was awarded maximum scores for partnerships toward sustainable healthcare, environmental reporting and social reporting. The company’s scores also rose significantly in the areas of risk management and customer relationship management.

November 16, 2021Fresenius Medical Care
Brief News
Fresenius Kabi enters collaboration to enhance controlled substance management in the U.S.

Fresenius Kabi and Omnicell, Inc are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Omnicell has designed new cassettes for its Controlled Substance Dispenser specifically for Fresenius Kabi Simplist® MicroVault® pre-filled syringes. The new cassettes provide customers with more flexibility and enhanced options for controlled substance management. The collaboration with Omnicell is an example of the continued investment Fresenius Kabi has made in its Simplist® portfolio. The investment has resulted in more Simplist® products for customers to choose from including those that offer radio frequency identification (RFID) technology.

November 10, 2021Fresenius Kabi

Fresenius improves FY/21 Group guidance for the second time after good Q3 results

November 02, 2021Fresenius
Fresenius Medical Care confirms outlook for 2021 while considering the continued negative impact of COVID-19

November 02, 2021Fresenius Medical Care

Fresenius Medical Care transforms its operating model, entering the next phase of its 2025 growth strategy

November 02, 2021Fresenius Medical Care
Fresenius Medical Care further enhances clinical care through continuous digital quality improvement

October 25, 2021Fresenius Medical Care

Brief News
Fresenius Kabi enters collaboration to enhance the supply of essential medicines for U.S. Patients

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

October 14, 2021Fresenius Kabi
Fresenius Medical Care donates 250,000 euros to UNICEF

October 04, 2021Fresenius Medical Care

Fresenius Medical Care publishes 2021 Global Annual Medical Report: Embracing the Complexity of Global Healthcare

September 23, 2021Fresenius Medical Care
Brief News
2022 DRG inflator for German hospitals set at 2.29%

The price increase for hospital services in Germany has been set at 2.29% for 2022. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 15, 2021Fresenius Helios

Fresenius Medical Care celebrates 25th anniversary

September 09, 2021Fresenius Medical Care
Brief News
Fresenius Helios publishes second sustainability report

Helios Germany has published its second sustainability report. The 60 pages report "Strong into the future" looks back on the complex challenges of the Corona year 2020 and shows in which areas the pandemic has driven developments for Germany’s largest private hospital operator. Helios Germany has defined four fields for its sustainability strategy: Patients, employees, the environment and compliance. Like the first report in 2019, it was drawn up based on the GRI standards of the Global Reporting Initiative and is now available in German on www.helios-gesundheit.de/nachhaltigkeit. An English version will be published soon.

September 08, 2021Fresenius Helios

Brief News
Biosimilar candidate of Fresenius Kabi shows positive results in two clinical trials

Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.

September 07, 2021Fresenius Kabi
Brief News
Fresenius Helios divests Volkach clinic

Fresenius Helios sells the clinic in Volkach near Würzburg, Germany, to Remedium Healthcare. A corresponding agreement on the 40-bed hospital also includes the transfer of two associated specialist centers in the region. The transaction is a first result of the ongoing strategic review and optimization of Helios' hospital portfolio. The transaction is expected to close by the first quarter of 2022 at the latest. Both sides have agreed not to disclose financial details.

September 07, 2021Fresenius Helios

Brief News
Fresenius Medical Care strengthens transplantation medicine

Fresenius Medical Care expands capabilities at its Global Medical Office: As part of a holistic approach to kidney therapy, the company aims to play an active role in the field of kidney transplantation. To achieve this, Fresenius Medical Care has created the position of Head of Transplantation Medicine and appointed Dr. Benjamin Hippen (49), a US citizen, to fill the post. In this role, he will lead the company’s worldwide efforts to expand access to and understanding of transplant medicine. Dr. Hippen is a distinguished general and transplant nephrologist. He previously served on the Board of Directors of InterWell Health in North America, a nephrology network in which Fresenius Medical Care participates.

September 06, 2021Fresenius Medical Care
Brief News
Helios acquires two hospitals in Kassel, Germany

Helios acquires the DRK (German Red Cross) Kliniken Nordhessen in Kassel with two clinics with a total of 433 beds and an associated outpatient care center (MVZ), which generated sales of around €87 million in 2020. The DRK-Schwesternschaft remains a co-partner. Together with the existing Helios hospital in Warburg, a regional medical cluster shall be formed and expanded over the next few years. The acquisition is expected to be completed in the fourth quarter of 2021. The purchase price is 1 euro and includes the assumption of debts and the securing of liquidity for current operations and for future investments.

September 02, 2021Fresenius Helios

Fresenius Medical Care increases investment in Humacyte, accompanies human acellular vessel developer’s stock market launch

August 30, 2021Fresenius Medical Care

Disclaimer All news

LATEST

November 02, 2021 - 01:30 PM | Bad Homburg, Germany

Conference Call Q3 2021, Fresenius

Live Webcast

Webcast Import (ICS) Investor News (PDF) Presentation (PDF) Transcript (PDF)

LATEST

Library

All Downloads

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us